Interaction of the Sodium/Glucose Cotransporter (SGLT) 2 inhibitor Canagliflozin with SGLT1 and SGLT2. (Q51737719)

http://europepmc.org/abstract/MED/27189972

11 April 2018

title

Interaction of the Sodium/Glucose Cotransporter (SGLT) 2 inhibitor Canagliflozin with SGLT1 and SGLT2. (English)

1 reference

http://europepmc.org/abstract/MED/27189972

11 April 2018

author

Suguru Okuda

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27189972%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

author name string

Ryuichi Ohgaki

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27189972%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

Ling Wei

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27189972%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

Kazunori Yamada

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27189972%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

Taiki Hara

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27189972%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

Chiaki Kuriyama

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27189972%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

Kiichiro Ueta

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27189972%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

Masaharu Shiotani

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27189972%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

Shushi Nagamori

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27189972%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

Yoshikatsu Kanai

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27189972%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

language of work or name

English

0 references

publication date

27 April 2016

1 reference

http://europepmc.org/abstract/MED/27189972

11 April 2018

published in

Journal of Pharmacology and Experimental Therapeutics

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27189972%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

volume

358

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27189972%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

page(s)

94-102

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27189972%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27189972%20AND%20SRC:MED&resulttype=core&format=json

Novel hypothesis to explain why SGLT2 inhibitors inhibit only 30-50% of filtered glucose load in humans

6 June 2020

cites work

1 reference

https://api.crossref.org/works/10.1124%2FJPET.116.232025

SGLT1 is a novel cardiac glucose transporter that is perturbed in disease states

21 January 2018

1 reference

https://api.crossref.org/works/10.1124%2FJPET.116.232025

Emerging sodium/glucose co-transporter 2 inhibitors for type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1124%2FJPET.116.232025

Paradoxical insights into whole body metabolic adaptations following SGLT2 inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1124%2FJPET.116.232025

Quantitative PCR tissue expression profiling of the human SGLT2 gene and related family members

21 January 2018

1 reference

https://api.crossref.org/works/10.1124%2FJPET.116.232025

Canagliflozin improves glycaemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1124%2FJPET.116.232025

Pharmacokinetics and pharmacodynamics of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in subjects with type 2 diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1124%2FJPET.116.232025

Effect of hepatic or renal impairment on the pharmacokinetics of canagliflozin, a sodium glucose co-transporter 2 inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1124%2FJPET.116.232025

Canagliflozin: first global approval

21 January 2018

1 reference

https://api.crossref.org/works/10.1124%2FJPET.116.232025

Kinetics of the reverse mode of the Na+/glucose cotransporter

21 January 2018

1 reference

https://api.crossref.org/works/10.1124%2FJPET.116.232025

Renal sodium glucose cotransporter 2 inhibitors as a novel therapeutic approach to treatment of type 2 diabetes: Clinical data and mechanism of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1124%2FJPET.116.232025

Regulation of the human Na+-dependent glucose cotransporter hSGLT2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1124%2FJPET.116.232025

SGLT2 inhibitors act from the extracellular surface of the cell membrane

21 January 2018

1 reference

https://api.crossref.org/works/10.1124%2FJPET.116.232025

Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1124%2FJPET.116.232025

Expression cloning and cDNA sequencing of the Na+/glucose co-transporter

21 January 2018

1 reference

https://api.crossref.org/works/10.1124%2FJPET.116.232025

Glucose transport by human renal Na+/D-glucose cotransporters SGLT1 and SGLT2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1124%2FJPET.116.232025

Pharmacokinetics, Pharmacodynamics, and Safety of Canagliflozin in Japanese Patients with Type 2 Diabetes Mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1124%2FJPET.116.232025

Pharmacokinetic and pharmacodynamic profiles of canagliflozin in Japanese patients with type 2 diabetes mellitus and moderate renal impairment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1124%2FJPET.116.232025

The human kidney low affinity Na+/glucose cotransporter SGLT2. Delineation of the major renal reabsorptive mechanism for D-glucose

21 January 2018

1 reference

https://api.crossref.org/works/10.1124%2FJPET.116.232025

Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1124%2FJPET.116.232025

Effect of canagliflozin on renal threshold for glucose, glycemia, and body weight in normal and diabetic animal models

21 January 2018

1 reference

https://api.crossref.org/works/10.1124%2FJPET.116.232025

Discovery of canagliflozin, a novel C-glucoside with thiophene ring, as sodium-dependent glucose cotransporter 2 inhibitor for the treatment of type 2 diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1124%2FJPET.116.232025

The effect of combined treatment with canagliflozin and teneligliptin on glucose intolerance in Zucker diabetic fatty rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1124%2FJPET.116.232025

Intestinal Sodium Glucose Cotransporter 1 Inhibition Enhances Glucagon-Like Peptide-1 Secretion in Normal and Diabetic Rodents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1124%2FJPET.116.232025

Sodium glucose transporter protein 2 inhibitors: focusing on the kidney to treat type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1124%2FJPET.116.232025

Canagliflozin lowers postprandial glucose and insulin by delaying intestinal glucose absorption in addition to increasing urinary glucose excretion: results of a randomized, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1124%2FJPET.116.232025

Transgenic knockdown of cardiac sodium/glucose cotransporter 1 (SGLT1) attenuates PRKAG2 cardiomyopathy, whereas transgenic overexpression of cardiac SGLT1 causes pathologic hypertrophy and dysfunction in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1124%2FJPET.116.232025

Transport of 3-fluoro-L-α-methyl-tyrosine by tumor-upregulated L-type amino acid transporter 1: a cause of the tumor uptake in PET.

21 January 2018

1 reference

https://api.crossref.org/works/10.1124%2FJPET.116.232025

Biology of human sodium glucose transporters

21 January 2018

1 reference

https://api.crossref.org/works/10.1124%2FJPET.116.232025

Molecular characteristics of Na(+)-coupled glucose transporters in adult and embryonic rat kidney

21 January 2018

1 reference

https://api.crossref.org/works/10.1124%2FJPET.116.232025

Human cardiomyocytes express high level of Na+/glucose cotransporter 1 (SGLT1)

21 January 2018

1 reference

https://api.crossref.org/works/10.1124%2FJPET.116.232025

21 January 2018

Identifiers

DOI

10.1124/JPET.116.232025

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27189972%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

1 reference